Annual CFF
$1.19 M
-$9.41 M-88.77%
01 December 2023
Summary:
Altamira Therapeutics annual cash flow from financing activities is currently $1.19 million, with the most recent change of -$9.41 million (-88.77%) on 01 December 2023. During the last 3 years, it has fallen by -$18.22 million (-93.87%). CYTO annual CFF is now -97.63% below its all-time high of $50.17 million, reached on 31 December 2014.CYTO Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
N/A
01 June 2024
Summary:
Altamira Therapeutics quarterly cash flow from financing activities is not available.CYTO Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
N/A
01 June 2024
Summary:
Altamira Therapeutics TTM cash flow from financing activities is not available.CYTO TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CYTO Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -88.8% | - | - |
| 3 y3 years | -93.9% | - | - |
| 5 y5 years | -79.5% | - | - |
CYTO Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -93.9% | at low | ||||
| 5 y | 5 years | -93.9% | at low | ||||
| alltime | all time | -97.6% | at low |
Altamira Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | $1.19 M(-88.8%) | - | - |
| Dec 2022 | $10.60 M(+46.6%) | - | - |
| Dec 2021 | $7.24 M(-62.7%) | - | - |
| Dec 2020 | $19.41 M(+155.0%) | - | - |
| Dec 2019 | $7.61 M(+30.8%) | - | - |
| Dec 2018 | $5.82 M(-31.0%) | $3.97 M(-20.0%) | $5.82 M(+97.6%) |
| Sept 2018 | - | $4.96 M(-179.9%) | $2.95 M(-183.5%) |
| June 2018 | - | -$6.21 M(-299.8%) | -$3.53 M(-227.6%) |
| Mar 2018 | - | $3.11 M(+185.2%) | $2.77 M(-67.2%) |
| Dec 2017 | $8.44 M(-24.8%) | $1.09 M(-171.9%) | $8.44 M(+31.4%) |
| Sept 2017 | - | -$1.52 M(-1919.0%) | $6.42 M(-68.0%) |
| June 2017 | - | $83.30 K(-99.1%) | $20.09 M(+0.4%) |
| Mar 2017 | - | $8.78 M(-1045.3%) | $20.01 M(+78.2%) |
| Dec 2016 | $11.23 M | -$929.00 K(-107.6%) | $11.23 M(-4.9%) |
| Sept 2016 | - | $12.16 M(<-9900.0%) | $11.81 M(-950.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2016 | - | -$1900.00(<-9900.0%) | -$1.39 M(-106.6%) |
| Mar 2016 | - | $0.00(-100.0%) | $21.15 M(-0.1%) |
| Dec 2015 | $21.16 M(-57.8%) | -$350.00 K(-66.2%) | $21.16 M(+11.1%) |
| Sept 2015 | - | -$1.04 M(-104.6%) | $19.04 M(-73.8%) |
| June 2015 | - | $22.54 M(>+9900.0%) | $72.82 M(+44.8%) |
| Mar 2015 | - | $12.40 K(-100.5%) | $50.28 M(+0.2%) |
| Dec 2014 | $50.17 M(+17.5%) | -$2.47 M(-104.7%) | $50.17 M(-26.8%) |
| Sept 2014 | - | $52.74 M(>+9900.0%) | $68.54 M(+304.2%) |
| June 2014 | - | $500.00(-100.5%) | $16.96 M(-58.7%) |
| Mar 2014 | - | -$98.20 K(-100.6%) | $41.03 M(-3.9%) |
| Dec 2013 | $42.68 M(+909.0%) | $15.90 M(+1275.4%) | $42.68 M(+59.4%) |
| Sept 2013 | - | $1.16 M(-95.2%) | $26.78 M(+4.5%) |
| June 2013 | - | $24.07 M(+1448.1%) | $25.63 M(+1548.1%) |
| Mar 2013 | - | $1.55 M | $1.55 M |
| Dec 2012 | $4.23 M | - | - |
FAQ
- What is Altamira Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Altamira Therapeutics?
- What is Altamira Therapeutics annual CFF year-on-year change?
- What is the all time high quarterly CFF for Altamira Therapeutics?
- What is the all time high TTM CFF for Altamira Therapeutics?
What is Altamira Therapeutics annual cash flow from financing activities?
The current annual CFF of CYTO is $1.19 M
What is the all time high annual CFF for Altamira Therapeutics?
Altamira Therapeutics all-time high annual cash flow from financing activities is $50.17 M
What is Altamira Therapeutics annual CFF year-on-year change?
Over the past year, CYTO annual cash flow from financing activities has changed by -$9.41 M (-88.77%)
What is the all time high quarterly CFF for Altamira Therapeutics?
Altamira Therapeutics all-time high quarterly cash flow from financing activities is $52.74 M
What is the all time high TTM CFF for Altamira Therapeutics?
Altamira Therapeutics all-time high TTM cash flow from financing activities is $72.82 M